Bictegravir 50mg / Emtricitabine 200mg / Tenofovir alafenamide 25mg tablets
NHS hospitals in England used £207,983,828 of indicative cost of Bictegravir 50mg / Emtricitabine 200mg / Tenofovir alafenamide 25mg tablets in the 12 months to April 2026, about 0.8% of all hospital medicines spend. That is up 2.2% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Bictegravir 50mg / Emtricitabine 200mg / Tenofovir alafenamide 25mg tablets: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Bictegravir 50mg / Emtricitabine 200mg / Tenofovir alafenamide 25mg tablets most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Chelsea & Westminster Hospital Nhs Ft | £30,270,154 |
| Manchester University Nhs Ft | £15,226,048 |
| Royal Free London Nhs Foundation Trust | £11,147,555 |
| Aintree University Hospital Nhs Ft | £10,119,671 |
| Western Sussex Hospitals Nhs Found Trust | £6,968,680 |
| Guy's & St Thomas' Nhs Foundation Trust | £6,801,632 |
| Imperial College Healthcare Nhs Trust | £6,560,148 |
| University College London Foundation Tr | £6,067,915 |
| University Hpls Of Leicester Nhs Trust | £5,872,957 |
| King's College Hpl Nhs Foundation Trust | £5,650,119 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.